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István Baczkó, Danina M. Muntean, and Norbert Jost
Abstract: A substantial body of evidence indicates that pharmacological activation of mitochondrial ATP-sensitive potassium
channels (mKATP) in the heart is protective in conditions associated with ischemia/reperfusion injury. Several mechanisms have
been postulated to be responsible for cardioprotection, including the modulation of mitochondrial respiratory function. The
aim of the present study was to characterize the dose-dependent effects of novel synthetic benzopyran analogues, derived from
a BMS-191095, a selective mKATP opener, on mitochondrial respiration and reactive oxygen species (ROS) production in isolated
rat heart mitochondria. Mitochondrial respiratory function was assessed by high-resolution respirometry, and H2O2 production
was measured by the Amplex Red fluorescence assay. Four compounds, namely KL-1487, KL-1492, KL-1495, and KL-1507, applied
in increasing concentrations (50, 75, 100, and 150 mol/L, respectively) were investigated. When added in the last two
concentrations, all compounds significantly increased State 2 and 4 respiratory rates, an effect that was not abolished by
5-hydroxydecanoate (5-HD, 100 mol/L), the classic mKATP inhibitor. The highest concentration also elicited an important
decrease of the oxidative phosphorylation in a K+ independent manner. Both concentrations of 100 and 150 mol/L for
KL-1487, KL-1492, and KL-1495, and the concentration of 150 mol/L for KL-1507, respectively, mitigated the mitochondrial
H2O2 release. In isolated rat heart mitochondria, the novel benzopyran analogues act as protonophoric uncouplers of
oxidative phosphorylation and decrease the generation of reactive oxygen species in a dose-dependent manner.
Key words: rat heart mitochondria, benzopyran analogues, protonophores, uncoupling, hydrogen peroxide.
Résumé : De plus en plus de données indiquent que l’activation pharmacologique des canaux potassiques sensibles a` l’ATP de
la mitochondrie (mKATP) du cœur le protège lorsqu’il est exposé a` des conditions associées au dommage d’ischémie/reperfusion.
Plusieurs mécanismes pourraient être responsables de la cardioprotection incluant la modulation de la fonction respiratoire
mitochondriale. Le but de l’étude présente était de caractériser les effets liés a` la dose de nouveaux analogues synthétiques du
benzopyrane, dérivés du BMS-191095, un composé qui ouvre sélectivement les mKATP, sur la respiration mitochondriale et la
production d’espèces réactives d’oxygène (ERO) dans les mitochondries isolées du cœur de rat et ce. La fonction respiratoire
mitochondriale a été évaluée par respirométrie a` haute résolution et la production de H2O2 a été mesurée par un dosage en
fluorescence a` l’aide de la trousse Amplex Red. Quatre composés, a` savoir KL-1487, KL-1492, KL-1495 et KL-1507, ajoutés en
concentrations croissantes (50, 75, 100 et 150mol/L, respectivement), ont été examinés. Lorsqu’ajoutés aux deux concentrations
les plus élevées, tous les composés accroissaient significativement les taux respiratoires aux états 2 et 4, effet qui n’était pas aboli
par le 5-hydroxydécanoate (5-HD, 100 mol/L), l’inhibiteur classique des mKATP. La plus forte concentration induisait aussi une
diminution importante de la phosphorylation oxydative demanière indépendante du K+. Les deux concentrations de 100 mol/L
et 150 mol/L de KL-1487, KL-1492 et KL-1495, et la concentration de 150 mol/L de KL-1507 diminuaient respectivement la
libération de H2O2 de la mitochondrie. Les nouveaux analogues du benzopyrane agissent comme découplants protonophores de
la phosphorylation oxydative dans les mitochondries isolées du cœur de rat, et diminuent la génération d’espèces réactives
d’oxygène en fonction de leur concentration. [Traduit par la Rédaction]
Mots-clés : mitochondries du cœur de rat, analogues du benzopyrane, protonophores, effet découplant, peroxyde d’hydrogène.
Introduction
In the past decades mitochondria have emerged as major con-
tributors to the pathogenesis of myocardial ischemia/reperfusion
(I/R) injury as well as important therapeutic targets in cardiopro-
tection (Camara et al. 2011; Di Lisa et al. 2007). The mitochondrial
ATP-sensitive potassium channel (mKATP) is one of the putative
structures at the inner mitochondrial membrane that has been
extensively studied in several experimental models as a major
target that can be modulated by pharmacological agents and
conditioning strategies to protect the heart against the deleteri-
ous effects of reoxygenation/reperfusion (critically reviewed by
Hanley and Daut (2005). The channel functions as potassium uni-
porter, allowing the ions intake into the matrix and is inhibited
by ATP, ADP, and fatty acids (Cardoso et al. 2010; Garlid and
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Halestrap 2012). Despite the fact that the first reconstitution of the
mKATP protein isolated from bovine heart in liposomes had been
reported more than two decades ago (Paucek et al. 1992), the mo-
lecular structure of the channel still remains inconclusive; there-
fore, the role in cardioprotection and, even their existence, has
been recently questioned (Garlid and Halestrap 2012).
Several research groups performed over the years a thorough
functional characterization using the pharmacological approach,
i.e., application of channel openers (agonists) or blockers (antago-
nists) and provided evidence for the role of mKATP in the regulation
ofmitochondrialmatrix volume, calciumuptake, respiration, and
reactive oxygen species (ROS) generation (reviewed in Ardehali and
O’Rourke (2005) andNishida et al. (2010)). It has also been reported
that potassium channel openers act as uncoupling protonophores
and thus contribute to cardioprotection (Holmuhamedov et al. 2004).
The role of mKATP in preventing the oxidative stress is particu-
larly important during the postischemic reperfusion, when mito-
chondria are both sources and targets of the oxidative burst (Di
Lisa 2001; Turrens 2003). The contribution of channel’s opening to
ROS production is controversial, since both a decrease (Ferranti
et al. 2003; Vanden Hoek et al. 2000) and an increase in mitochon-
drial ROS in the presence of mKATP agonists (Forbes et al. 2001;
Krenz et al. 2002; Liu et al. 1998; Pain et al. 2000) have been re-
ported in the literature.
One of the confounding factors regarding the pharmacological
approach in studies reporting on cardioprotective effects of
mKATP openers is related to the lack of selectivity of the first
developed agonists that were able to activate both the mitochon-
drial and sarcolemmal ATP-sensitive channels (Hanley and Daut
2005). In the attempt to increase the selectivity versus mKATP,
several benzopyran conjugates have been developed and tested in
the past years (reviewed in Breschi et al. (2006)). Among these
compounds, BMS-191095 is a 4-(N-aryl)-substituted benzopyran re-
puted to have the highest mKATP selectivity and anti-ischemic
potency (Mannhold 2004). Its beneficial effects were demon-
strated not only in the heart (Grover et al. 2001, 2002) but also in
cultured cortical neurons (Gaspar et al. 2008; Mayanagi et al.
2007), and a skeletal muscle cell line (Malinska et al. 2010).
The present study was aimed at characterizing the effects of
four novel synthetic benzopyran compounds (Fig. 1), structural
analogues of BMS–191095 that have been proposed to act asmKATP
openers, onmitochondrial respiration and ROS release in isolated
rat heart mitochondria.
Materials and methods
All experimental procedures were conducted in accordance
with Directive 2010/63/EU and the corresponding Romanian law
nr. 43/May 2014 regarding the protection of animals used for sci-
entific purposes, respectively. The experimental protocol was ap-
proved by the Committee for Research Ethics of “Victor Babeş”
University for Medicine and Pharmacy of Timis¸oara, Romania.
Experiments were performed on Sprague Dawley (SD) adult
female rats (4–6 months, n = 5–6/group). Animals were fed ad
libitum and housed under standard conditions (constant temper-
ature and humidity of 22.5 ± 2 °C and 55 + 5%, 12 h light/dark cycle).
Twenty-four hours prior to experiment, solid food was withdrawn
with no limitation in water supply.
Rat heart mitochondria (RHM) isolation
Rats were anesthetized by the intraperitoneal administration of
a mixture of ketamine (30 mg/kg) and xylazine (5 mg/kg). Hearts
were rapidly excised and immersed in 20 mL isolation medium
(100mmol/L sucrose, 50mmol/L KCl, 20mmol/L TES-2-[(2-hydroxy-
1,1-bis(hydroxymethyl)ethyl)amino]ethanesulfonic acid, 1 mmol/L
EDTA, 0.2% bovine serum albumin (BSA), pH 7.2 at 4 °C). Separate
experiments were performed in mitochondria isolated in K+ free
medium (220 mmol/L manitol, 70 mmol/L sucrose, 5 mmol/L N-
[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid (TES),
0.5 mmol/L EGTA, supplemented with 2 mg/mL bovine serum
albumin (BSA), pH 7.4, adjusted with Trizma base; 2 °C). Ventric-
ular tissue was manually triturated with subtilisin (5 mg/g wet
tissue), a non-specific protease, to release the interfibrillar mito-
chondria. The suspension was homogenised with a tissue homog-
enizer (Glas-Col 099C K5424 CE) for maximum 30 s. The final
tissue homogenate obtained was processed at 4 °C using the dif-
ferential centrifugation technique as previously described (Duicu
et al. 2013). Mitochondrial protein concentration was determined
using biuret method (Gornall et al. 1949).
High-resolution respirometry experiments
Oxygen consumption was measured at 37 °C by high-resolution
respirometry (HRR) with the Oxygraph-2k (Oroboros Instruments,
Austria). RHM (0.1 mg proteins/mL) were incubated in 2 mL of
incubation medium (0.5 mmol/L EGTA, 3 mmol/L MgCl2·6H2O,
60 mmol/L K-lactobionate, 20 mmol/L taurine, 10 mmol/L KH2P04,
20 mmol/L HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic)
acid, 110 mmol/L sucrose, 1 g/L BSA, essentially free fatty acid +
280 U/mL catalase lyophilized powder, 2000–5000 units/mg pro-
tein, at pH 7.1, 37 °C). In separate experiments, mitochondrial
respiratory rates were measured in KCl incubation medium
(120 mmol/L KCl, 5 mmol/L KH2PO4, 5 mmol/L TES, and 1 mmol/L
MgCl2, pH 7.4, adjusted with Trizma base at 37 °C) or in choline
chloride medium (120 mmol/L choline chloride, 5 mmol/L NaH2PO4,
5 mmol/L TES, and 1 mmol/L MgCl2, pH 7.4, adjusted with Trizma
base at 37 °C).
The substrate-uncoupler-inhibitor-titration (SUIT) protocol,
GMState2 + ADPOXPHOS + c + OmyState4 + FCCPETS + (Ama)ROX, was
previously described (Duicu et al. 2013) and comprised the fol-
lowing steps: (i) addition of complex I respiratory substrates,
10 mmol/L glutamate (G) and 2 mmol/L malate (M), State 2 (basal
respiration); (ii) addition of 5 mmol/L adenosine diphosphate
(ADP) to assess the maximal oxidative phosphorylation capacity
(OXPHOS), State 3 (active respiration); (iii) addition of 10 mol/L
cytochrome c (c) to check for the integrity of mitochondrial outer
membrane; (iv) addition of 2 g/mL oligomycin (Omy), an F0F1-ATP
synthase inhibitor, to inhibit State 3 at the level of State 4; (v) suc-
cessive titrations (0.5 mol/L steps) with FCCP (carbonyl cyanide
p-(trifluoro-methoxy) phenyl-hydrazone) to obtain the uncoupled
respiration and to measure the electron transport system capac-
ity, ETS; (vi) inhibition of respiration with 2.5 mol/L antimycin A
(Ama) to measure the residual oxygen consumption, ROX state.
Mitochondrial respiration was corrected for oxygen flux due to
instrumental background and ROX. The respiratory control ratio
(RCR) was calculated as the ratio OXPHOS/State 4.
Assessment of hydrogen peroxide (H2O2) production
Mitochondrial H2O2 release was measured using the Amplex
Red (10 mol/L) fluorescent marker (wavelengths: excitation at
530 nm and emission at 590 nm, Hitachi F-7000 spectrofluorimeter)
as previously described (Duicu et al. 2013). RHM (0.25mgprotein/mL)
were incubated in 2 mL incubation buffer (250 mmol/L sucrose,
1 mmol/L EGTA, 1 mmol/L EDTA, 20 mmol/L Tris/HCl, and 1.5 mg/mL
defatted BSA, pH 7.4, 37 °C), supplemented with CI-dependent
substrates: G (5 mmol/L) and M (5 mmol/L). At the beginning of
each measurement, the background fluorescence was quantified
by adding known amounts of H2O2 to the incubation buffer, in the
absence of mitochondria. Net fluorescence was then calculated
by measuring the fluorescence variation in function of time,
minus background, and H2O2 production was expressed in
pmol H2O2/min/mg proteins.
Chemicals
The benzopyran analogues were synthesized by Kiss Lorand at
the Institute of Pharmaceutical Chemistry, Faculty of Pharmacy,
University of Szeged, Hungary. Calcium Green-5N and Amplex
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Red were purchased from Invitrogen. All the other chemicals
were from Sigma-Aldrich.
Statistical analysis
Data were expressed as means ± SEM. Data analysis used one-
way ANOVA followed by a post-hoc Tukey’s multiple comparison
test (GraphPadPrism v. 5.0 Software, SUA). The difference was
considered statistically significant if p < 0.05.
Results and discussion
High-resolution respirometry
Four benzopyran derivatives, namely KL-1487, KL-1492, KL-1495,
and KL-1507, in increasing concentrations (50, 75, 100, and
150mol/L, respectively) were screened. Stock solutions of benzopyran
analogues were made up in DMSO (60 mmol/L) and then serially
diluted to give the abovementioned concentrations. Thefinal DMSO
concentrationwas constant (0.25%) throughout the experiments and
did not influence the respiratory rates (data not shown).
The major finding of this work is that we report a dose-
dependent modulation of the mitochondrial respiratory function
for all investigated compounds. Accordingly, a significant in-
crease in respiratory State 4 (Table 1, Fig. 2) was recordedwhen the
compounds were added in the highest concentrations (150 and
100 mol/L). The maximum increase was found for KL-1492, while
the lowest yet significant change was found in the case of KL-1507
(Table 1, Fig. 2).
However, when applied in the maximal concentration (150 mol/L),
all compounds induced a significant decrease in OXPHOS (State 3,
ADP-stimulated respiration) vs. control (Ctrl), with the most im-
portant inhibition recorded for KL-1487 (Table 1, Fig. 3). These
effects (increase in State 4 together with the decrease in OXPHOS)
for 150 mol/L resulted in a significant reduction of the respira-
tory index (OXPHOS/State 4) vs. Ctrl for all tested compounds
(Table 1, Fig. 4).
As mentioned in the previous section, State 2 represents the
basal respiration, whereas State 4 was pharmacologically induced
Fig. 1. Chemical structures of the four synthetic benzopyran analogues.








KL-1487 150 M 74,2% 96.4% 76.3%
KL-1487 100 M — 78.4% —
KL-1492 150 M 57,7% 140.8% 80.4%
KL-1492 100 M — 74.8% 56.43%
KL-1495 150 M 56.7% 104% 79%
KL-1495 100 M — 64% 71.62%
KL-1507 150 M 48.3% 64.6% 37.58%
KL-1507 100 M — 64.2% —
Note: Data are expressed as percentage changes of mitochondrial respiratory
rates in treated groups vs. Ctrls (100%).
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with oligomycin (Omy), which inhibits the proton entry at the
level of F0-ATPase. Compounds able to stimulate respiratory rates
in State 4 (and 2) in a dose-dependent fashion are known as uncou-
plers, because they disrupt (or uncouple) the link between substrate
oxidation and ADP phosphorylation in ATP. Conversely, mitochon-
drial respiration that has been inhibited by inhibitors such as anti-
mycin cannot be released by the uncouplers (Terada 1990).
Data presented in this study suggest that all four investigated
compounds act as inhibitory uncouplers, showing an intrinsic
uncoupling effect with increasing concentrations and inhibitory
property when used in the highest doses. Indeed, starting from
50 mol/L, these benzopyran analogues uncoupled the oxidative
phosphorylation of mitochondria respiring on the NAD-dependent
substrates glutamate-malate.
We further tested the effects of 5-hydroxydecanoate (5-HD,
100mol/L), which is known as putative selectivemKATP inhibitor.
Our data clearly demonstrated that the uncoupling effect induced
by all four benzopyran analogues was not abolished by 5-HD
Fig. 2. State 4 respiratoy rates in the presence of K-1487, KL-1492, KL-1495, and KL-1507. Results are expressed in pmol/(s·mL). Values are
means ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001 vs. Ctrl).
Fig. 3. OXPHOS respiratory rates in the presence of K-1487, KL-1492, KL-1495, and KL-1507. Results are expressed in pmol/(s·mL). Values are
means ± SEM (**p < 0.01; ***p < 0.001 vs. Ctrl).
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(Table 2), suggesting that the increase in CI-supported basal respi-
ration was not related to the opening of mKATP channels. Our
findings agrees with the well-established effects of the mKATP
openers, diazoxide and pinacidil, that act as uncoupling protono-
phores, mainly when applied in high concentrations, in isolated
rodentmitochondrial preparations (Drose et al. 2006; Hanley et al.
2002; Holmuhamedov et al. 2004; Kopustinskiene et al. 2002;
Korotkov et al. 2006; Kowaltowski et al. 2001) in a potassium
channel-independent manner. Also, our data regarding the effect
of 5-HD are in agreement with the previous reports showing that
the mKATP blocker had no effect on the activation of the basal
mitochondrial respiration by diazoxide and pinacidil applied in
similar concentrations (Kopustinskiene et al. 2010; Korotkov et al.
2006). Furthermore, all four compounds significantly decreased
State 3 respiration as was earlier demonstrated for diazoxide
(Kopustinskiene et al. 2002; Rousou et al. 2004) and pinacidil
(Kopustinskiene et al. 2010).
To investigate whether the decrease of State 3 respiratory rate
can be assigned to the mKATP opening, we recapitulated the ex-
periments onmitochondria isolated in free potassiummedia, and
wemeasured the respiratory rates in potassium chloride and cho-
line chloride medium (without K+). Since the effect of all four
compounds at 150 mol/L on State 3 respiration remained un-
changed (Fig. 5) no relation with the K+ flux into thematrix can be
affirmed. This observation is in line with the results reported for
pinacidil in the same experimental model by Toleikis’ group
(Kopustinskiene et al. 2010), who found a K+-independent decrease
in State 3 and, also in uncoupled respiration, in the presence of
complex I respiratory substrates.
It has to be mentioned that the most investigated benzopyrane
derivate, BMS 191095, was reported to exert cytoprotective effect
against a calcium ionophore-induced injury in a skeletal muscle
cell line C2C12 (Malinska et al. 2010); the compound promoted
cellular survival despite an impaired mitochondrial function, as
shown by a decrease in State 3 respiration. Interestingly, cytopro-
tection against calcium overload elicited by the specific mKATP
opener was not reversed in this model by 5-HD, the channel in-
hibitor applied in high concentration (500 mol/L). Whether this
might be related to the previously reported inhibition of respira-
tion by high concentrations (100 and 300 mol/L) of 5-HD is not
known (Lim et al. 2002). Moreover, the beneficial neuroprotective
effects of BMS 191095 against cerebral ischemia could be reversed
only when 5-HD was applied in very high (10 and 20 mmol/L)
concentrations (Mayanagi et al. 2007). However, it cannot be ruled
out in these models that, as shown for diazoxide, the ability of
5-HD to reverse protection elicited by channel openers is related
to its metabolic effects and does not result frommKATP inhibition
(Hanley et al. 2005).
Collectively, our data show a significant uncoupling effect of
these novel benzopyran analogues at 100 and 150 mol/L concen-
tration and the inhibition of mitochondrial respiration when
the compounds were applied in the highest concentration
(150 mol/L) in isolated rat heart mitochondria. These effects are
not related to the activation of mKATP channels, but they are
rather suggestive for a protonophoric action, as reported for the
prototype mKATP openers, diazoxide, in the pioneering studies of
Fig. 4. RCR in the presence of K-1487, KL-1492, KL-1495, and KL-1507. Values are means ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001 vs. Ctrl).
Table 2. HRR studies for CI-supported respiration in the presence of
5-hydroxydecanoic acid (5-HD).
OXPHOS State 4 RCR
Ctrl 711.8±87.2 68.5±7.3 8.2±1.1
KL-1487 183.6±13.5* 134.5±17.61* 1.929±0.35*
KL-1487 + 5-HD 185.8±17.03* 135.4±40.4* 1.7±0.5*
Ctrl 589.5±43.65 72.37±3.5 7.927±0.41
KL-1492 250.8±39.81* 174.3±25.85* 1.553±0.2*
KL-1492 + 5-HD 242.6±27.3* 214.2±23.8* 1.15±0.55*
Ctrl 443.4±37 74.61±5.2 6.6±0.71
KL-1495 192.1±46.07* 147.2±6.2* 1.383±0.3*
KL-1495 + 5-HD 212.3±32.22* 153.4±13* 1.45±0.3*
Ctrl 656.4±49.04 55.28±3.25 6.22±0.46
KL-1507 339.5±42.16* 151.0±7.7* 3.8±0.5*
KL-1507 + 5-HD 341.2±32.6* 155.1±9* 3.3±0.3*
Note:Data are expressed in pmol/(s·mL). Values aremeans ± SEM (*p<0.05 vs. Ctrl.).
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Portenhauser et al. (1971) and more recently, for diazoxide and
pinacidil (Holmuhamedov et al. 2004; Kowaltowski et al. 2001).
However, several issues that remain to be clarified can be re-
garded as limitations of the present study. First, assessing the
effect of BSA on the uncoupling effect is worthy, since it has been
reported that the uncoupling effect of diazoxide was significantly
depressed by BSA in the incubation medium (Kopustinskiene
et al. 2010). Furthermore, since the uncoupling effect can also be
determined by the opening of the mitochondrial permeability
transition pore (mPTP), the effect of a mPTP desensitizer (e.g.,
cyclosporine A) on the increased State 4 respiratory rates will be
assessed.
Fig. 5. HRR studies for OXPHOS rates in choline chloride (ChoCl) medium vs. KCl medium. Results are expressed in pmol/(s·ml). Values are
means ± SEM (*p < 0.05; **p < 0.01 vs. Ctrl).
Fig. 6. Assessment of H2O2 release in mitochondria respiring on glutamate/malate. Results are expressed in pmol/(mg prot·min). Values are
means ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001 vs. Ctrl).
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In the second part of the study we addressed the effect of these
four benzopyran compounds on ROS released by isolated mito-
chondria respiring in the presence of CI substrates (glutamate-
malate), using the Amplex Red assay. Our results show a significant
decrease of mitochondrial H2O2 for the first three compounds
(KL-1487, KL-1492, and KL-1495) when applied at 100 and 150 mol/L
(Fig. 6) and only in the presence of the highest concentration in
the case of KL-1507, respectively (Fig. 6). Interestingly, the last
compound KL-1507 showed a slight increase in ROS production
when applied at 100 mol/L, whereas the highest concentration
elicited a significant decrease of H2O2 release (Fig. 6).
Our data confirm previous studies reporting on the ability of
the mKATP openers to protect mitochondria function and struc-
ture by suppressing ROS generation during reoxygenation (Ferranti
et al. 2003; Ozcan et al. 2002; Vanden Hoek et al. 2000).
In the past decade the interest of the scientific community
largely moved towards the pharmacological modulation of the
mitochondrial permeability transition pore (mPTP) as novel mito-
chondrial target for cardioprotection (recently reviewed in Bernardi
and Di Lisa (2015)), while studies addressing mKATP channels
mainly attempted to elucidate its structure (Foster et al. 2012).
Besides the unequivocal role ofmKATP openers in reducing infarct
size, an emerging research direction is represented by their role
in preserving the electrical stability of the heart (reviewed in
Muntean et al. (2015)). Interestingly, a functional crosstalk be-
tween mPTP and mKATP that determined the arrhythmic vulner-
ability to oxidative stress has been recently reported (Xie et al.
2014).
The selective benzopyran derivate, BMS 191095, elicited both
antinecrotic (Neckar et al. 2002) and antiarrhythmic (Fischbach
et al. 2004) protection in the rodent heart subjected to I/R injury,
being recognized as an useful tool for basic research (Grover and
Atwal 2002). Accordingly, further studies addressing the role of
novel benzopyran analogues in preventing the deleterious effects
of reperfusion injury are warranted. Whether their above re-
ported effects can be recapitulated in the settings of I/R injury
remains to be demonstrated. Indeed, different behaviours may
arise in pathological conditions, since as pointed out in a critical
review by Brookes (2005), “uncoupling of mitochondria decreases
ROS but uncoupling of inhibited mitochondria increases ROS”.
Nevertheless, mKATP andmPTP represent targets for pharmaco-
logical interventions that could be jointly applied to mitigate one
of the major consequences of mitochondria dysfunction, namely
the oxidative stress, and thus to provide better cardioprotection.
Conclusions
KL-1487, KL-1492, KL-1495, and KL-1507 are novel benzopyran
analogues with protonophoric properties that modulate mito-
chondrial respiratory function and hydrogen peroxide release in
isolated rat heart mitochondria respiring on physiological com-
plex I substrates. High-resolution respirometry studies conducted
in the presence of the pharmacological modulators of mKATP re-
vealed the uncoupling effect and respiratory inhibition, respec-
tively, in a K+ independent manner. Moreover, when applied in
the highest concentrations, all the investigated compounds de-
creased H2O2 release. Whether these effects can be associated
with cardioprotection in the setting of ischemia/reperfusion in-
jury remains to be demonstrated.
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